Cite
MLA Citation
Sam Keeping et al.. “Pembrolizumab versus the standard of care for relapsed and refractory classical Hodgkin's lymphoma progressing after brentuximab vedotin: an indirect treatment comparison.” Expert review of hematology, vol. 11, no. 6, 2018, pp. 503–511. http://access.bl.uk/ark:/81055/vdc_100064996908.0x000009